Launched during RANZCO’s virtual congress, Quantel Medical’s C.Stim offers new intense pulsed light (IPL) technology for the treatment of the root causes of dry eye: meibomian gland dysfunction, inflammation and Demodex.
The US Food and Drug Administration (FDA) has approved the first generic of Allergan’s Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use eye drops to increase tear production in dry eye patients.
Focusing on dry eye disease (DED), the third Ocular Therapeutics Evening (OTE) finally went ahead after a five-month wait. It’s been a while since we had an in-person meeting, so it was great to see at least the top halves of some familiar faces again! It was also entertaining to see the Covid trace
Alcon has expanded its range of preservative-free eye drops for dry eye disease with the addition of Systane Complete Preservative-Free. Using Systane’s delivery system of hydroxypropyl-guar
Alcon has expanded its range of preservative-free eye drops for dry eye disease with the addition of Systane Complete Preservative-Free. Using Systane’s delivery system of hydroxypropyl-guar (HP-Guar)
A 52-year-old South-East Asian female presented to clinic for a routine eye exam. She had been experiencing some near blur and a constant gritty sensation in both eyes; otherwise, she had no notable symptoms. Her last medical exam was six months prior and she had hypercholesterolaemia that was under
Glaukos has enrolled its first patient for its phase 2 trials of GLK-301, a pilocarpine-based cream applied to the outer eyelid to treat dry eye disease (DED). The California-based ophthalmic
Lumenis is hosting a Dry Eye Summit live at the Sydney Hilton Hotel, providing an opportunity for educational discussion, collaboration and networking. The event will feature presentations from three
Of all the things we’ve had enough of lately, screen time is surely one. We might be navigating endless spreadsheets, overlapping Zoom meetings, frustrating home schooling, or helplessly doom-scrolling at midnight, but we’re also extremely fortunate to be able to learn and connect online.
Aerie Pharmaceuticals announced significant increases in tear production in the phase 2b study of its dry-eye disease (DED) drops AR-15512, which it says also create a cooling sensation on the
Sight Sciences’ TearCare system for the treatment of meibomian gland dysfunction (MGD) has received the US Food and Drug Administration’s (FDA) 510(K) device clearance. Designed for adult patients
The Centre for Ocular Research and Education (CORE) has released an update exploring whether increasing use of screens affects ocular comfort and can ultimately lead to dry eye
